Saccharomyces Cerevisiae for Irritable Bowel Syndrome

• Status: Completed
• Trial end date: 2021-10-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to see the response of saccharomyces cerevisiae for symptomatic improvement of patients with IBS

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ziauddin University
• Collaborator: Hilton Pharma

Criteria

Inclusion Criteria:

• Male and female patients between 18 and 75 years of age,

• Patients having confirmed IBS according to Rome IV criteria (newly and previously non-responder to treatment),

• Pain/ discomfort score strictly above 1 and strictly below 6 as determined on a pain/ discomfort scale using arbitrary grading from 0 to 7 in 7 days preceding the inclusion visit,

• Not hypersensitive to any of the ingredients of the drug.

Exclusion Criteria:

• Patients with an organic intestinal disease (Crohn's disease, ulcerative colitis, etc.),

• Pregnant females

• Treatments likely to influence IBS (anti-depressants, opioids, and narcotic analgesics)

• Patients with chronic alcoholism, vegetarian or vegan regimens

• Eating disorders such as anorexia or bulimia

• Documented food allergies.